0/510596 #a

DT04 REC POTIPTO 0 7 OCT 200 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Based on PCT/JP03/04396

Filed:

Intl. Filing 07 APRIL 2003

Art Unit: Examiner:

tba tha

1st Inventor

II. Masavuki

Allowed:

For:

Severe Sepsis Preventive Therapeutic Agent

Batch:

Atty, Dkt. No.

3039 US0P

Paper No.:

Information Disclosure Statement

MAIL STOP PCT P.O. Box 1450 Commissioner for Patents Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the references listed on the attached Forms PTO/SB/08A and 08B. A legible copy of each listed reference is herewith being provided to the Examiner.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call applicants' attorney at (847) 383-3372.

Respectfully submitted,

Dated: 10/4/0

(847) 383-3372 (847) 383-3391 Mark Chao, Ph.D., Reg. No. 37,293 Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc. Intellectual Property Department 475 Half Day Road Lincolnshire, IL 60069 USA

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of inform ation unless it contains a valid OMB control number

Substitute for form 1449/PTO

Sheet 2

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 3

/Shobha Kantamneni/

Based on PCT/JP03/04396 Application Number Filing Date Intl. Filing 07 APRIL 2003 First Named Inventor II, Masayuki Art Unit tba Examiner Name tba Attorney Docket Number 3039 US0P

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ^{2 (F known)}			Figures Appear
		US-			1
		us-			
		US-		-	
		US-			
		US-	1		
		US-			
		US-			
		US-			
	1	US-			
		us-	†		
	_	119.			

			PATENT DOCU	IMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Peges, Columns, Lines, Where Relevant Pesseges	
		Country Code ⁵ "Number ⁴ "Kind Code ⁶ (if known)	MM-DD-YYYY		Or Relevent Figures Appear	T°
7S.K./	A7	EP 1348443 A1	10/01/2003	Takeda Chemical Ind.		V
/S.K./	A8	WO 01/72993 A1-Abstract only	10/04/2001	Mochida Pharmaceutical Co.		
/S.K./	A9	WO 01/36488 A1	05/25/2001	Leiv Eiriksson Nyfotek AS		~
	_		 			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not **Exchanges** Initial if internoc consistency, whether or not clation is in confermance with MPEP 600. Draw line through Citation if not in profit Codes of consistent includes or consistency of the form when exchanges on the construction is purposed. Application and profit codes of codes of the form when exchanges or consistency is consistent in the codes of codes of the codes of th Translation is attached.

Oate

Considered

07/23/2009

Intrastation is actorition.

This collection of information is required by 37 CFR 1.97 and 1.99. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.SC. 122 and 37 CFR 1.4. This collection is estimated to task 2 hours to complete, including gathering, preparing, and sumfitting the completed application from the MSPTO. This will very depending upon the includings and a second of the control of the post of the pos TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

07/23/2009

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark (Effice; U.S. Dez/ARI INICRI Or Communication of Information unless I containing a valid OMS control number.

Complete if Knowing | 1 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100

Sheet 1

Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of 3

/Shobha Kantamneni/

Application Number Based on PCT/JP03/04396 Intl. Filing 07 APRIL 2003 Filing Date First Named Inventor II, Masayuki Art | Init tba tba

Attorney Docket Number 3039 USOP

U. S. PATENT DOCUMENTS Document Number Publication Date MM-DD-YYYY Name of Patentee or Peges, Columns, Lines, Where Applicant of Cited Document want Passages or Relevant Figures Appear Initials* Nο Number-Kind Code^{2 (F known)} HS. 118 HS. US-110. TIS. US-US-US-ŪS-US-US-US-US-US-US-IIIS. US-

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pessages Or Relevant Figures Appear	Т		
		Country Code ³ "Number ⁴ "Kind Code ⁵ (If known)	MM-DD-YYYY			Te		
/S.K./	A1	JP 2001-261557A - Abstract only	09/26/2001	Takeda Chemical Ind.				
/S.K./	A2	EP 1063228 A1	12/27/2000	Takeda Chemical Ind.		V		
/S.K./	A3	EP 1209149 A1	05/29/2002	Takeda Chemical Ind.		V		
/S.K./	A4	WO 99/25834	05/27/1999	Genentech, Inc.		V		
/S.K./	A5	WO 99/20756	04/29/1999	Genentech, Inc.		V		
/S.K./	A6	WO 98/33524	08/06/1998	Kenneth L. Becker, etal.		V		

Considered EXAMINER: Initial if elierence considered, whether or not clasion is in conformance with MPEP 509. Draw line through leation if not in conformance and not considered, include copy of this form with next communication to epipicant. Applicant's unique clastion designation number (optional): See finise Codes or USPPO retains to seek include code (MPPO Standard ST.3). For use or use of the retain of the Emperor must provide the serial number of the patient document. When of document to the opportunities symbols es includated on the document under MPPO Standard ST.9 for possible. Application is to picca or check mark have if English lenguage

Translation is attached.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

Un	der the Paperwork Red	uction A	t of 1995, no persons ar		of Information unless it contains a valid OMB control number.	
	te for form 1449/PTO			Complete if Known 1 / 5 1059		
1				Application Number	Based on PCT/JP03/04396	
			CLOSURE	Filing Date	Intl. Filing 07 APRIL 2003	
STA	TEMENT E	SY A	PPLICANT	First Named Inventor	II, Masayuki	1
	(Use as many she	ate ae n	oressand	Art Unit	tba	
	(000 to many one			Examiner Name	tba	
Sheet	3	of	3	Attorney Docket Number	3039 US0P	

A

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	Cite No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/S.K./	A10	THIERRY ROGER, et al., "MIF Regulates Innate Immune Responses Through Modulation of Toll-like Receptor 4", Nature, (2001), pp. 920-924, Vol. 414	~
		·	
-			

Examiner Signature	/Shobha Kantamneni/	Date Considered	07/23/2009	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINE: Initial if reference considered, whether or not classion is in conformance with MPEP 600. Draw line through classion if not in conformance and not considered. Include copy of this form with nead communication in applicant.

I Applicant's unique clusters designation number (positions). *Applicant is not exceed to the conformance and not conformance and n